SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects

A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects


  • Org Study ID: CC-486-CAGEN-001
  • Secondary ID:
  • NCT ID: NCT02223052
  • NCT Alias:
  • Sponsor: Celgene - Industry
  • Source: Celgene

Brief Summary

This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension This study will enroll approximately 60 subjects in stage I and 60 subjects in stage II with hematologic or solid tumor malignancies, excluding gastrointestinal tumors and tumors that have originated or metastasized to the liver for which no standard treatment exists or have progressed or recurred following prior therapy. Subjects must not be eligible for therapy of higher curative potential where an alternative treatment has been shown to prolong survival in an analogous population. Approximately 23 sites in the US and 2 in Canada will participate in this study.

Detailed Description


Stage I - Pharmacokinetics (Bioequivalence)

Subjects will be randomized to receive CC-486 300 mg orally on each of the two
pharmacokinetic (PK) study days based on the dosing sequences they are randomized to:

Dosing Sequence 1: 2x150 mg tablets followed by 1x30 mg tablet. Dosing Sequence 2: 1x300 mg
tablet followed by 2x150 mg tablets. Each dose will be administered in the clinic at least 48
hours apart between PK dosing day 1 and PK dosing day 2 over a period no longer than 10 days
under fasted conditions.

Stage II - Pharmacokinetics (Food Effect)

Subjects will be randomized to receive CC-486 300 mg orally on each of the two PK study days
based on the dosing sequences they are randomized to:

Dosing Sequence 1: 1x300 mg tablet under fasted condition followed by 1x300 mg tablet under
fed condition.

Dosing Sequence 2: 1x300 mg tablet under fed condition followed by 1x300 mg tablet under
fasted condition.

Each dose will be administered in the clinic at least 48 hours apart between PK dosing day 1
and PK dosing day 2 over a period no longer than 10 days. The sponsor will generate the
randomization scheme and assign subjects upon enrollment to the appropriate sequence for
dosing:

Fasted condition: following an overnight fast of at least 10 hours, subjects will ingest oral
Azacitidine with 240 mL of room temperature water. Subjects must fast for a minimum of 4
hours following oral Azacitidine administration. Subjects may drink water as desired, except
for 1 hour before and 1 hour after oral Azacitidine administration.

Fed condition: following an overnight fast of at least 10 hours and following the performance
of all required pre-dose assessments, subjects randomized to receive test medication in a fed
state will begin ingesting a breakfast meal 30 (±5) minutes prior to the planned
administration of oral Azacitidine. They will continue the entire meal within 20 to 25
minutes (no less than 20 minutes) from the time the meal is served. Subjects will then ingest
oral Azacitidine with 240 mL of room temperature water. Subjects must fast a minimum of 4
hours following oral Azacitidine administration. Subjects may drink water as desired, except
for 1 hour before and 1 hour after administration of oral Azacitidine.

Extension Phase (for subjects who have completed PK Stage I or Stage II) Subjects continuing
beyond the pharmacokinetics phase (Stage I or Stage II) will enter the extension phase of the
study at the discretion of the investigator to receive < 6 (four-week) cycles of Vidaza 75
mg/m2 IV or SC daily for 7 days in the clinic and repeat every 4 weeks per prescribed label
at the discretion of the investigator for ≤ 6 (four-week) cycles.

Overal Status Start Date Phase Study Type
Recruiting October 27, 2014 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Pharmacokinetics Cmax - Stage I (Bioequivalence)

Primary Outcome 1 - Time Frame: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose

Primary Outcome 2 - Measure: Pharmacokinetics Tmax - Stage I (Bioequivalence)

Primary Outcome 2 - Time Frame: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose

Primary Outcome 3 - Measure: Pharmacokinetics AUC-t - Stage I (Bioequivalence)

Primary Outcome 3 - Time Frame: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose

Primary Outcome 4 - Measure: Pharmacokinetics AUC-infinity - Stage I (Bioequivalence)

Primary Outcome 4 - Time Frame: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose

Primary Outcome 5 - Measure: Pharmacokinetics λz (Terminal Rate) - Stage I (Bioequivalence)

Primary Outcome 5 - Time Frame: Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.3.5, 4, 6, and 8 hours post-dose

Primary Outcome 6 - Measure: Pharmacokinetics Terminal Half-Life (t½) - Stage I (Bioequivalence)

Primary Outcome 6 - Time Frame: Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose

Primary Outcome 7 - Measure: Pharmacokinetics Apparent total clearance (CL/F) - Stage I (Bioequivalence)

Primary Outcome 7 - Time Frame: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose

Primary Outcome 8 - Measure: Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage I (Bioequivalence)

Primary Outcome 8 - Time Frame: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose

Primary Outcome 9 - Measure: Pharmacokinetics Cmax - Stage II (Food Effect Bioavailability)

Primary Outcome 9 - Time Frame: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.

Primary Outcome 10 - Measure: Pharmacokinetics Tmax - Stage II (Food Effect Bioavailability)

Primary Outcome 10 - Time Frame: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.

Primary Outcome 11 - Measure: Pharmacokinetics AUC-t - Stage II (Food Effect Bioavailability)

Primary Outcome 11 - Time Frame: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.

Primary Outcome 12 - Measure: Pharmacokinetics AUC-infinity - Stage II (Food Effect Bioavailability)

Primary Outcome 12 - Time Frame: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.

Primary Outcome 13 - Measure: Pharmacokinetics λz (Terminal Rate) - Stage II (Food Effect Bioavailability)

Primary Outcome 13 - Time Frame: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.

Primary Outcome 14 - Measure: Pharmacokinetics Terminal Half-Life (t½) - Stage II (Food Effect Bioavailability)

Primary Outcome 14 - Time Frame: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.

Primary Outcome 15 - Measure: Pharmacokinetics Apparent total clearance (CL/F) - Stage II (Food Effect Bioavailability)

Primary Outcome 15 - Time Frame: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.

Primary Outcome 16 - Measure: Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage II (Food Effect Bioavailability)

Primary Outcome 16 - Time Frame: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.

Condition:

  • Hematological Neoplasms
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Lymphoma
  • Lymphoma
  • Multiple Myeloma
  • Acute Myeloid Leukemia
  • Leukemia
  • Myelodysplastic Syndromes
  • Neoplasms
  • Melanoma
  • Breast Cancer
  • Metastatic Breast Cancer
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
  • Glioblastoma Multiforme
  • Osteosarcoma
  • Sarcoma
  • Thyroid Cancer
  • Genitourinary

Eligibility

Criteria:
Inclusion Criteria:

- Subjects must satisfy the following criteria to be enrolled in the study:

1. Age ≥ 18 years of age at the time of signing the informed consent document.

2. Understand and voluntarily sign an informed consent document prior to any study
related assessments/procedures are conducted.

3. Documented diagnosis of any of the following:

1. Myelodysplastic Syndrome (MDS) according to the World Health Organization
(WHO) 2008 classification

2. Acute myeloid leukemia (AML)

3. Multiple myeloma (MM), limited to those patients for whom standard curative
or palliative treatments do not exist or are no longer effective

4. Non-Hodgkin's lymphoma (NHL), limited to those patients for whom standard
curative or palliative treatment do not exist or are no longer effective,

5. Hodgkin's lymphoma (HL), limited to those patients for whom standard
curative or palliative treatment do not exist or are no longer effective

6. Metastatic or inoperable solid tumors* (except gastrointestinal tumors or
tumors that originated or metastasized to the liver) for which no standard
treatment exists, or have progressed or recurred following prior therapy.

- Subjects must not be eligible for therapy of higher curative potential
where an alternative treatment has been shown to prolong survival in an
analogous population.

4. Patients with a history of treated brain metastases should be clinically stable
for ≥ 4 weeks prior to signing the informed consent. Glucocorticoid therapy for
central nervous system (CNS) edema is permitted if ≤ 20 mg of prednisolone (or
equivalent).

5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

6. Have a life expectancy of ≥ 3 months.

7. Have stable renal function without dialysis for at least 2 months prior to
Investigational Product (IP) administration defined by:

1. Serum creatinine < 2.5 x the upper limit of normal (ULN)

2. An average calculated creatinine clearance > 30 mL/min/1.73 m^2

8. Have organ and marrow function at the screening and pre-dose visits as defined
by:

1. Hemoglobin ≥ 8 g/dL

2. Absolute neutrophil count (ANC) ≥ 0.75 x 10^3/uL without treatment with a
myeloid growth factor within 3 days prior to first dose of IP

3. Platelets ≥ 30 x 10^3/uL

4. Total bilirubin ≤ 1.5 x Upper Limits of Normal (ULN)

5. Aspartate aminotransferase (AST) ≤ 2 x ULN

6. Alanine aminotransferase (ALT) ≤ 2 x ULN

9. Have a 12-lead Electrocardiogram (ECG) that is not clinically significant at
screening, as determined by the investigator

10. Females of childbearing potential (FCBP) may participate, providing the subject
meets the following conditions:

- Agree to use at least two effective contraceptive methods (oral, injectable,
or implantable hormonal contraceptive; tubal ligation; intra-uterine device;
barrier contraceptive with spermicide; or vasectomized partner) or agree to
practice true abstinence throughout the study, and for 3 months following
the last dose of IP; and

- Negative serum pregnancy test at screening (sensitivity of at least 25
mIU/mL); (Note that the screening serum pregnancy test can be used as the
test prior to starting IP in the pharmacokinetics phase if it is performed
within the 72-hour timeframe), and

- Negative serum or urine pregnancy test (investigator's discretion;
sensitivity of at least 25 mIU/mL) within 72 hours prior to starting IP in
the extension phase. (Note: subjects must have negative serum or urine
pregnancy test prior to dosing on Day 1 of each treatment cycle in the
extension phase.)

11. Male subjects must:

a. Practice true abstinence* or agree to the use of at least two
physician-approved contraceptive methods throughout the course of the study and
should avoid fathering a child during the course of the study for at least 3
months following the last dose of IP.

* True abstinence is acceptable when this is in line with the preferred and usual
lifestyle of the patient. [Periodic abstinence (e.g., calendar, ovulation,
symptothermal, post-ovulation methods) and withdrawal are not acceptable methods
of contraception].

12. Able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

1. Women who are pregnant or nursing (lactating).

2. Gastrointestinal tumors, tumors that have originated or metastasized to the liver, or
other tumors known to interfere with the absorption, distribution, metabolism, or
excretion of drugs.

3. Had chemotherapy or radiotherapy within 4 weeks prior to the first day of
Investigational Product (IP) administration.

4. Have been treated with an investigational agent within 4 weeks prior to the first day
of IP administration.

5. Have ongoing clinically significant adverse event(s) due to prior treatments
administered as determined by the investigator.

6. Significant active cardiac disease within the previous 6 months, including:

- New York Heart Association (NYHA) class IV congestive heart failure

- Significant cardiac arrhythmia or unstable angina or angina requiring surgical or
medical intervention; and/or

- Myocardial infarction

7. Have known or suspected hypersensitivity to azacitidine or any other ingredient used
in the manufacturing of Azacitidine.

8. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing
signs/symptoms related to the infection without improvement despite appropriate
antibiotics, antiviral therapy, and/or other treatment)

9. History of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis),
celiac disease, prior gastrectomy, gastric bypass, upper bowel removal, or any other
gastrointestinal disorder or defect that would interfere with the absorption of the
study drug and/or predispose the subject to an increased risk of gastrointestinal
toxicity.

10. Any significant medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from participating in the study.

11. Any condition including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study

12. Any condition that confounds the ability to interpret data from the study

13. Impaired ability to swallow oral medication

14. Any condition that confounds the ability to interpret data from the study
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Du Lam, MD

Role: Study Director

Affiliation: Celgene

Overall Contact

Name: Michael Pinho

Phone:

Email: mpinho@celgene.com

Locations

Facility Status Contact
Scottsdale Healthcare Research Institute
Scottsdale, Arizona 85258
United States
Completed
Mayo Clinic - Arizona
Scottsdale, Arizona 85259
United States
Recruiting
University of Arizona Cancer Center
Tucson, Arizona 85724
United States
Recruiting
University of Iowa
Iowa City, Iowa 52242
United States
Recruiting
Henry Ford Health System
Detroit, Michigan 48202-268
United States
Recruiting
Veteran Affairs Medical Center, Research #517
Kansas City, Missouri 64128
United States
Not yet recruiting
Cancer Institute of New Jersey
New Brunswick, New Jersey 08903
United States
Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
Recruiting
Greenville Hospital System
Greenville, South Carolina 29605
United States
Recruiting
Vanderbilt- Ingram Cancer Center
Nashville, Tennessee 37232-6307
United States
Recruiting
The Methodist Hospital Research Institute l
Houston, Texas 77030
United States
Recruiting